TNYA
Tenaya Therapeutics, Inc.
Biotechnology
Market Cap$184M
5Y Perf.-94.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TNYA vs RCKT
Revenue, margins, valuation, and 5-year total return — side by side.
RCKT
Rocket Pharmaceuticals, Inc.
Biotechnology
Market Cap$398M
5Y Perf.-89.8%
TNYA vs RCKT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TNYA | RCKT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $184M | $398M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-91M | $-223M |
| Total Debt | $11M | $25M |
| Cash & Equiv. | $101M | $78M |
TNYA vs RCKT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TNYA
RCKT
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Tenaya Therapeutics… (TNYA) | 100 | 5.5 | -94.5% |
| Rocket Pharmaceutic… (RCKT) | 100 | 10.2 | -89.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TNYA vs RCKT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TNYA and RCKT are tied at the top with 2 categories each — the right choice depends on your priorities. Rocket Pharmaceuticals, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
TNYA
Tenaya Therapeutics, Inc.
The Growth Play
TNYA has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- EPS growth 55.0%
- Lower volatility, beta 2.80, Low D/E 8.8%, current ratio 6.84x
- 11.8% revenue growth vs RCKT's 10.5%
Best for: growth exposure and sleep-well-at-night
RCKT
Rocket Pharmaceuticals, Inc.
The Income Pick
RCKT is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.31
- -91.3% 10Y total return vs TNYA's -94.5%
- Beta 1.31, current ratio 6.38x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TNYA | 11.8% revenue growth vs RCKT's 10.5% |
| Stability / Safety | RCKT | Beta 1.31 vs TNYA's 2.80 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TNYA | +88.6% vs RCKT's -45.2% |
| Efficiency (ROA) | RCKT | -67.5% ROA vs TNYA's -70.0%, ROIC -63.2% vs -103.2% |
TNYA vs RCKT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCKTLAGGINGTNYA
TNYATenaya Therapeutics, …
1leads
RCKTRocket Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs TNYAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TNYA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RCKT4/6
Risk & VolatilityBeta, volatility, and downside exposure
RCKT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TNYA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TNYA and RCKT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$93M | -$232M |
| Net IncomeAfter-tax profit | -$91M | -$223M |
| Free Cash FlowCash after capex | -$69M | -$190M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +57.1% | +38.7% |
TNYA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TNYA and RCKT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| Market CapShares × price | $184M | $398M |
| Enterprise ValueMkt cap + debt − cash | $94M | $345M |
| Trailing P/EPrice ÷ TTM EPS | -1.44x | -1.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.05x | 1.47x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — TNYA and RCKT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — TNYA and RCKT each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
RCKT delivers a -80.5% return on equity — every $100 of shareholder capital generates $-80 in annual profit, vs $-85 for TNYA. TNYA carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCKT's 0.09x. On the Piotroski fundamental quality scale (0–9), TNYA scores 4/9 vs RCKT's 1/9, reflecting mixed financial health.
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -85.2% | -80.5% |
| ROA (TTM)Return on assets | -70.0% | -67.5% |
| ROICReturn on invested capital | -103.2% | -63.2% |
| ROCEReturn on capital employed | -79.3% | -58.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.09x | 0.09x |
| Net DebtTotal debt minus cash | -$90M | -$53M |
| Cash & Equiv.Liquid assets | $101M | $78M |
| Total DebtShort + long-term debt | $11M | $25M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Evenly matched — TNYA and RCKT each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RCKT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCKT five years ago would be worth $838 today (with dividends reinvested), compared to $553 for TNYA. Over the past 12 months, TNYA leads with a +88.6% total return vs RCKT's -45.2%. The 3-year compound annual growth rate (CAGR) favors RCKT at -44.4% vs TNYA's -49.0% — a key indicator of consistent wealth creation.
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +15.4% | +6.1% |
| 1-Year ReturnPast 12 months | +88.6% | -45.2% |
| 3-Year ReturnCumulative with dividends | -86.7% | -82.8% |
| 5-Year ReturnCumulative with dividends | -94.5% | -91.6% |
| 10-Year ReturnCumulative with dividends | -94.5% | -91.3% |
| CAGR (3Y)Annualised 3-year return | -49.0% | -44.4% |
RCKT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
RCKT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RCKT is the less volatile stock with a 1.31 beta — it tends to amplify market swings less than TNYA's 2.80 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCKT currently trades 49.7% from its 52-week high vs TNYA's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.80x | 1.31x |
| 52-Week HighHighest price in past year | $2.35 | $7.39 |
| 52-Week LowLowest price in past year | $0.36 | $2.19 |
| % of 52W HighCurrent price vs 52-week peak | +36.1% | +49.7% |
| RSI (14)Momentum oscillator 0–100 | 57.3 | 54.4 |
| Avg Volume (50D)Average daily shares traded | 4.2M | 3.5M |
RCKT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TNYA as "Buy" and RCKT as "Buy". Consensus price targets imply 174.6% upside for TNYA (target: $2) vs 36.2% for RCKT (target: $5).
| Metric | TNYATenaya Therapeuti… | RCKTRocket Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $2.33 | $5.00 |
| # AnalystsCovering analysts | 6 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCKT leads in 2 of 6 categories (Total Returns, Risk & Volatility). TNYA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallRocket Pharmaceuticals, Inc. (RCKT)Leads 2 of 6 categories
Loading custom metrics...
TNYA vs RCKT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TNYA or RCKT a better buy right now?
Analysts rate Tenaya Therapeutics, Inc.
(TNYA) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TNYA or RCKT?
Over the past 5 years, Rocket Pharmaceuticals, Inc.
(RCKT) delivered a total return of -91. 6%, compared to -94. 5% for Tenaya Therapeutics, Inc. (TNYA). Over 10 years, the gap is even starker: RCKT returned -91. 3% versus TNYA's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TNYA or RCKT?
By beta (market sensitivity over 5 years), Rocket Pharmaceuticals, Inc.
(RCKT) is the lower-risk stock at 1. 31β versus Tenaya Therapeutics, Inc. 's 2. 80β — meaning TNYA is approximately 113% more volatile than RCKT relative to the S&P 500. On balance sheet safety, Tenaya Therapeutics, Inc. (TNYA) carries a lower debt/equity ratio of 9% versus 9% for Rocket Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — TNYA or RCKT?
On earnings-per-share growth, the picture is similar: Tenaya Therapeutics, Inc.
grew EPS 55. 0% year-over-year, compared to 26. 4% for Rocket Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TNYA or RCKT?
Tenaya Therapeutics, Inc.
(TNYA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Rocket Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TNYA leads at 0. 0% versus 0. 0% for RCKT. At the gross margin level — before operating expenses — TNYA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TNYA or RCKT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TNYA or RCKT better for a retirement portfolio?
For long-horizon retirement investors, Rocket Pharmaceuticals, Inc.
(RCKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Tenaya Therapeutics, Inc. (TNYA) carries a higher beta of 2. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RCKT: -91. 3%, TNYA: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TNYA and RCKT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.